Women’s Health Bulletin

Published by: Kowsar

The Effect of Ramadan Fasting on Hypothalamic Pituitary Ovarian (HPO) Axis in Women with Polycystic Ovary Syndrome

Farideh Zangeneh 1 , * , Nasrin Abedinia 2 , Mohammad Mehdi Naghizadeh 3 , Reza Salman Yazdi 4 and Tahereh Madani 5
Authors Information
1 Vali-e-Asr Reproductive Health Research Center, Imam Complex Hospital, Research Institute for Islamic and Complementary Medicine (RICM), Iran University of Medical Sciences, Tehran, IR Iran
2 Maternal, Fetal‐Neonatal Research Center, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Community Medicine, Medical Faculty, Fasa University of Medical Sciences, Fasa, IR Iran
4 Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, IR Iran
5 Department of Gynecology and Female Infertility, Royan Institute, Tehran, IR Iran
Article information
  • Women's Health Bulletin: April 1, 2014, 1 (1); e18962
  • Published Online: April 1, 2014
  • Article Type: Research Article
  • Received: October 10, 2013
  • Revised: November 23, 2013
  • Accepted: January 5, 2014
  • DOI: 10.17795/whb-18962

To Cite: Zangeneh F, Abedinia N, Mehdi Naghizadeh M, Salman Yazdi R, Madani T. The Effect of Ramadan Fasting on Hypothalamic Pituitary Ovarian (HPO) Axis in Women with Polycystic Ovary Syndrome, Women Health Bull. 2014 ; 1(1):e18962. doi: 10.17795/whb-18962.

Copyright © 2014, Health Policy Research Center, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Saper CB. The central circadian timing system. Curr Opin Neurobiol. 2013; 23(5): 747-51[DOI][PubMed]
  • 2. Pashaei A. Buddhism. 1347;
  • 3. Tabarsi FH. Javame Aljame. 1: 103
  • 4. Reilly T, Waterhouse J. Altered sleep-wake cycles and food intake: the Ramadan model. Physiol Behav. 2007; 90(2-3): 219-28[DOI][PubMed]
  • 5. Majlesi MB. Bahar al anvar. 1362; : 49
  • 6. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011; (7)[DOI][PubMed]
  • 7. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011; 3: 25-35[DOI][PubMed]
  • 8. Yen SSC. . Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. 1999; : 191–217
  • 9. Baker FC, Driver HS. Circadian rhythms, sleep, and the menstrual cycle. Sleep Med. 2007; 8(6): 613-22[DOI][PubMed]
  • 10. Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target? Clin Endocrinol (Oxf). 2012; 77(6): 791-801[DOI][PubMed]
  • 11. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010; 8: 41[DOI][PubMed]
  • 12. Adali E, Yildizhan R, Kurdoglu M, Kolusari A, Edirne T, Sahin HG, et al. The relationship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome. J Int Med Res. 2008; 36(6): 1188-96[PubMed]
  • 13. Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod. 2007; 22(8): 2279-86[DOI][PubMed]
  • 14. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003; (19): 41 –7
  • 15. Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target? Clin Endocrinol (Oxf). 2012; 77(6): 791-801[DOI][PubMed]
  • 16. Malyala A, Kelly MJ, Ronnekleiv OK. Estrogen modulation of hypothalamic neurons: activation of multiple signaling pathways and gene expression changes. Steroids. 2005; 70(5-7): 397-406[DOI][PubMed]
  • 17. Chen MD, O'Byrne KT, Chiappini SE, Hotchkiss J, Knobil E. Hypoglycemic 'stress' and gonadotropin-releasing hormone pulse generator activity in the rhesus monkey: role of the ovary. Neuroendocrinology. 1992; 56(5): 666-73[PubMed]
  • 18. Rabin DS, Johnson EO, Brandon DD, Liapi C, Chrousos GP. Glucocorticoids inhibit estradiol-mediated uterine growth: possible role of the uterine estradiol receptor. Biol Reprod. 1990; 42(1): 74-80[PubMed]
  • 19. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab. 1975; 40(5): 774-9[DOI][PubMed]
  • 20. Mastorakos G, Scopa CD, Kao LC, Vryonidou A, Friedman TC, Kattis D, et al. Presence of immunoreactive corticotropin-releasing hormone in human endometrium. J Clin Endocrinol Metab. 1996; 81(3): 1046-50[DOI][PubMed]
  • 21. Reyes BA, Glaser JD, Van Bockstaele EJ. Ultrastructural evidence for co-localization of corticotropin-releasing factor receptor and mu-opioid receptor in the rat nucleus locus coeruleus. Neurosci Lett. 2007; 413(3): 216-21[DOI][PubMed]
  • 22. Angelopoulos TJ, Denys BG, Weikart C, Dasilva SG, Michael TJ, Robertson RJ. Endogenous opioids may modulate catecholamine secretion during high intensity exercise. Eur J Appl Physiol Occup Physiol. 1995; 70(3): 195-9[PubMed]
  • 23. Curtis AL, Bello NT, Valentino RJ. Evidence for functional release of endogenous opioids in the locus ceruleus during stress termination. J Neurosci. 2001; 21(13)[PubMed]
  • 24. Zangeneh FZ, Mohammadi A, Ejtemaeimehr S, Naghizadeh MM, Fatemeh A. The role of opioid system and its interaction with sympathetic nervous system in the processing of polycystic ovary syndrome modeling in rat. Arch Gynecol Obstet. 2011; 283(4): 885-92[DOI][PubMed]
  • 25. Wallbridge DR, MacIntyre HE, Gray CE, Denvir MA, Oldroyd KG, Rae AP, et al. Increase in plasma beta endorphins precedes vasodepressor syncope. Br Heart J. 1994; 71(5): 446-8[PubMed]
  • 26. Naryzhnaia NV, Maslov LN, Revinskaia Iu G, Lishmanov Iu B. [Interrelations between sympathetic adrenal and opioid systems--regulatory mechanism determining cardiac resistance to stress damage]. Usp Fiziol Nauk. 2001; 32(4): 73-81[PubMed]
  • 27. Plotsky PM, Cunningham EJ, Widmaier EP. Catecholaminergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocr Rev. 1989; 10(4): 437-58[DOI][PubMed]
  • 28. Marshall JC. Endocrinology. 2001;
  • 29. Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann N Y Acad Sci. 1998; 851: 311-35[PubMed]
  • 30. Tsigos C, Chrousos GP. Physiology of the hypothalamic-pituitary-adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metab Clin North Am. 1994; 23(3): 451-66[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments